Literature DB >> 28839817

Managing acute severe ulcerative colitis in the hosptialised setting.

David McClements1, Chris Probert1.   

Abstract

Ulcerative colitis affects approximately 146 000 people in the UK and is the most common form of inflammatory bowel disease. The majority of patients will have uncomplicated disease, but around 1 in 10 patients will develop acute severe colitis. Despite modern medical management, colectomy rates of 27% and mortality rates of 1% are still reported. Good supportive care and intravenous corticosteroids remain the mainstay of treatment, but up to one-third of patents will not respond. The Travis criteria allow early recognition of those patients failing to improve by day 3, allowing timely planning of medical rescue therapy or surgery. Rescue therapy with either infliximab or ciclosporin appears equally efficacious. Patients naive to thiopurines seem to have better colectomy-free survival rates following rescue therapy than those previously exposed. We review the published evidence behind the conventional management of acute severe ulcerative colitis.

Entities:  

Keywords:  Ulcerative Colitis

Year:  2014        PMID: 28839817      PMCID: PMC5369586          DOI: 10.1136/flgastro-2014-100459

Source DB:  PubMed          Journal:  Frontline Gastroenterol        ISSN: 2041-4137


  37 in total

1.  Cortisone in ulcerative colitis; final report on a therapeutic trial.

Authors:  S C TRUELOVE; L J WITTS
Journal:  Br Med J       Date:  1955-10-29

2.  A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis.

Authors:  G J Mantzaris; K Petraki; E Archavlis; P Amberiadis; D Kourtessas; A Christidou; G Triantafyllou
Journal:  Scand J Gastroenterol       Date:  2001-09       Impact factor: 2.423

3.  Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis.

Authors:  J Panés; M Esteve; E Cabré; J Hinojosa; M Andreu; M Sans; F Fernandez-Bañares; F Feu; M A Gassull; J M Piqué
Journal:  Gastroenterology       Date:  2000-10       Impact factor: 22.682

4.  Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.

Authors:  B E Sands; W J Tremaine; W J Sandborn; P J Rutgeerts; S B Hanauer; L Mayer; S R Targan; D K Podolsky
Journal:  Inflamm Bowel Dis       Date:  2001-05       Impact factor: 5.325

5.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

Authors:  Gunnar Järnerot; Erik Hertervig; Ingalill Friis-Liby; Lars Blomquist; Per Karlén; Christer Grännö; Mogens Vilien; Magnus Ström; Ake Danielsson; Hans Verbaan; Per M Hellström; Anders Magnuson; Bengt Curman
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

6.  Ciclosporin use in acute ulcerative colitis: a long-term experience.

Authors:  Simon Campbell; Simon Travis; Derek Jewell
Journal:  Eur J Gastroenterol Hepatol       Date:  2005-01       Impact factor: 2.566

7.  Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis.

Authors:  Gert Van Assche; Geert D'Haens; Maja Noman; Séverine Vermeire; Martin Hiele; Katrien Asnong; Joris Arts; Andre D'Hoore; Freddy Penninckx; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682

8.  Low molecular weight heparin (tinzaparin) vs. placebo in the treatment of mild to moderately active ulcerative colitis.

Authors:  S Bloom; S Kiilerich; M R Lassen; A Forbes; K Leiper; E Langholz; E J Irvine; C O'Morain; D Lowson; S Orm
Journal:  Aliment Pharmacol Ther       Date:  2004-04-15       Impact factor: 8.171

9.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

Authors:  C S J Probert; S D Hearing; S Schreiber; T Kühbacher; S Ghosh; I D R Arnott; A Forbes
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

10.  Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis.

Authors:  Joris Arts; Geert D'Haens; Miranda Zeegers; Gert Van Assche; Martin Hiele; André D'Hoore; Freddy Penninckx; Severine Vermeire; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-03       Impact factor: 5.325

View more
  1 in total

1.  High Remission Rate with Infliximab and Plant-Based Diet as First-Line (IPF) Therapy for Severe Ulcerative Colitis: Single-Group Trial.

Authors:  Mitsuro Chiba; Tsuyotoshi Tsuji; Kunio Nakane; Satoko Tsuda; Hajime Ishii; Hideo Ohno; Yu Obara; Masafumi Komatsu; Haruhiko Tozawa
Journal:  Perm J       Date:  2020-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.